- Home
- HIVE vs ORKA Comparison
HIVE vs ORKA Comparison
Compare HIVE & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- ORKA
- Stock Information
- Founded
- HIVE 1987
- ORKA 2004
- Country
- HIVE United States
- ORKA United States
- Employees
- HIVE N/A
- ORKA N/A
- Industry
- HIVE
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HIVE
- ORKA Health Care
- Exchange
- HIVE Nasdaq
- ORKA Nasdaq
- Market Cap
- HIVE 360.2M
- ORKA 354.2M
- IPO Year
- HIVE N/A
- ORKA N/A
- Fundamental
- Price
- HIVE $2.30
- ORKA $14.21
- Analyst Decision
- HIVE Strong Buy
- ORKA Strong Buy
- Analyst Count
- HIVE 7
- ORKA 8
- Target Price
- HIVE $6.57
- ORKA $39.71
- AVG Volume (30 Days)
- HIVE 24.0M
- ORKA 360.1K
- Earning Date
- HIVE 08-11-2025
- ORKA 08-15-2025
- Dividend Yield
- HIVE N/A
- ORKA N/A
- EPS Growth
- HIVE N/A
- ORKA N/A
- EPS
- HIVE N/A
- ORKA N/A
- Revenue
- HIVE $115,279,000.00
- ORKA N/A
- Revenue This Year
- HIVE $167.38
- ORKA N/A
- Revenue Next Year
- HIVE $68.08
- ORKA N/A
- P/E Ratio
- HIVE N/A
- ORKA N/A
- Revenue Growth
- HIVE 0.71
- ORKA N/A
- 52 Week Low
- HIVE $1.26
- ORKA $5.49
- 52 Week High
- HIVE $5.54
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- HIVE 66.14
- ORKA N/A
- Support Level
- HIVE $2.09
- ORKA N/A
- Resistance Level
- HIVE $2.44
- ORKA N/A
- Average True Range (ATR)
- HIVE 0.18
- ORKA 0.00
- MACD
- HIVE 0.04
- ORKA 0.00
- Stochastic Oscillator
- HIVE 80.46
- ORKA 0.00
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.